The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia
Open Access
- 16 June 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (12) , 2177-2182
- https://doi.org/10.1016/j.jacc.2004.02.052
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Molecular and Cellular Mechanisms of Myocardial StunningPhysiological Reviews, 1999
- Assessment of Left-Ventricular FunctionThe Thoracic and Cardiovascular Surgeon, 1998
- Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytesEuropean Journal of Pharmacology, 1997
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Effects of Levosimendan, a Cardiotonic Agent Targeted to Troponin C, on Cardiac Function and on Phosphorylation and Ca 2+ Sensitivity of Cardiac Myofibrils and Sarcoplasmic Reticulum in Guinea Pig HeartCirculation Research, 1995
- Mechanisms of Action of Calcium-Sensitizing DrugsJournal of Cardiovascular Pharmacology, 1995
- Myofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium.Circulation, 1994
- Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: A regional wall motion analysisJournal of the American College of Cardiology, 1991
- Mechanism of myocardial "stunning".Circulation, 1990
- Quantitative assessment of regional left ventricular motion using endocardial landmarksJournal of the American College of Cardiology, 1986